Revenue
2014
2015
2016
2017
2018
2023
2024
2025
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $263.5M | $164.1M | $1.2M | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | — | — |
| Research & development | $300.3M | $276.2M | $333.2M | $294.8M | $259.0M | $201.7M | $166.0M | $99.8M | $71.6M | $26.9M | $15.5M | $3.8M | $2.2M | $1.7M | $1.8M | $171,484 | $0 | — |
| Operating expenses | — | — | — | $398.9M | $342.7M | $261.9M | $206.9M | $128.3M | $92.9M | $53.6M | $27.9M | $12.0M | $22.6M | $8.1M | $21.2M | $815,413 | $15,772 | — |
| Operating income | −$403.4M | −$395.3M | −$460.6M | −$398.9M | −$342.7M | −$261.9M | −$206.9M | −$128.3M | −$92.9M | −$53.6M | −$27.9M | −$12.0M | −$22.6M | −$8.1M | −$21.2M | −$815,413 | −$15,772 | — |
| EBITDAderived | −$390.5M | −$384.0M | −$449.0M | −$389.6M | −$339.6M | −$260.8M | −$205.7M | −$127.3M | −$91.9M | −$52.7M | −$26.9M | −$12.0M | −$22.6M | −$8.1M | −$21.2M | −$756,816 | −$14,440 | — |
| Net income | −$391.0M | −$372.2M | −$444.0M | −$395.9M | −$342.3M | −$259.6M | −$197.6M | −$123.6M | −$92.1M | −$52.9M | −$27.7M | −$12.0M | −$25.4M | −$3.3M | −$25.7M | −$1.6M | −$15,772 | −$58,716 |
| Basic EPSper diluted share | -$1.09 | -$1.28 | -$1.89 | -$2.49 | -$2.23 | -$1.88 | -$1.59 | -$1.27 | -$1.41 | -$1.85 | -$0.62 | -$0.48 | -$3.47 | -$4.14 | -$0.34 | -$0.02 | $0.00 | — |
| Diluted EPSper diluted share | -$1.09 | -$1.28 | -$1.89 | -$2.49 | -$2.23 | -$1.88 | -$1.59 | -$1.27 | -$1.41 | -$1.85 | -$0.62 | -$0.48 | -$3.47 | -$4.14 | -$0.34 | -$0.02 | $0.00 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 5, 2025Form 4 | Kirby Daniel GordonChief Commercial Officer | BuyCommon Stock | 30.0K | $1.84 | $55.2K | 30.0K |
| May 23, 2025Form 4 | Puri Raj K.Chief Regulatory Officer | BuyCommon Stock | 5.6K | $1.74 | $9.7K | 206.9K |
| May 14, 2025Form 4 | Vogt Frederick GInterim CEO & General Counsel | BuyCommon Stock | 25.0K | $1.69 | $42.3K | 374.6K |
| Nov 12, 2024Form 4 | Maynard Ryan DDirector | SellCommon Stock | 50.0K | $10.06 | $503.0K | 7.5K |